gemlapodect (NOE-105) / Noema Pharma |
2021-004424-15: A study to evaluate different doses of a medicine called NOE-105 for the treatment of patients with Tourette Syndrome. |
|
|
| Not yet recruiting | 2 | 18 | Europe | NOE-105, Capsule | Noema Pharma Australia Pty Ltd, Noema Pharma Australia Pty Ltd | Tourette Syndrome, Facial and vocal tics, Diseases [C] - Nervous System Diseases [C10] | | | | |
ACTRN12621000319875: An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult male patients with Tourette Syndrome (TS). |
|
|
| Recruiting | 2 | 10 | | | Noema Pharma Australia Pty Ltd, Noema Pharma Australia PTY LTD | Tourette syndrome | | | | |
NCT05583955: A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) |
|
|
| Completed | 2 | 75 | US, RoW | NOE-105, Escalating dose levels of NOE-105, Placebo, Placebo to match | Noema Pharma AG | Childhood-Onset Fluency Disorder | 10/23 | 11/23 | | |
| Not yet recruiting | 2 | 180 | NA | Gemlapodect, NOE-105, Placebo | Noema Pharma AG | Tourette Syndrome | 12/26 | 12/26 | | |
RG7203: RG7203: P1 for Schizophrenia |
|
|
| Available | 1 | 0 | RoW | RG7203 | Roche | Schizophrenia | | | | |